For GSK, Lots Of Drugs In R&D, But Many Are Long-Term
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline PLC held an expansive R&D update Nov. 3, laying out a strategy to file up to 20 drugs with regulators before 2020, seven of which could launch in that timeline. But few investors are likely to walk away from the four-hour meeting with a changed sentiment on the firm in the near-term, where it is facing strong headwinds from slowing sales of its top-seller Advair Diskus.
